Robert Montal

romontal@clinic.cat

Publicaciones destacadas

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

Autores:
Montal R; Andreu-Oller C; Bassaganyas L; Esteban-Fabró R; Moran S;

(...)

Villanueva A; Sia D; Mazzaferro V; Esteller M; Llovet JM.

Referencia: BRITISH JOURNAL OF CANCER 2019.
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

Autores:
Llovet JM; Montal R; Villanueva A;

Referencia: JOURNAL OF HEPATOLOGY, SUPPLEMENT 2019.
New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

Autores:
Montironi C; Montal R; Llovet JM;

Referencia: CLINICAL LIVER DISEASE 2019.
Molecular therapies and precision medicine for hepatocellular carcinoma

Autores:
Llovet J; Montal R; Sia D; Finn R;

Referencia: Nature Reviews Clinical Oncology 2018.
Molecular Classification and Potential Therapeutic Targets in Extrahepatic Cholangiocarcinoma

Autores:
Montal, Robert; Leow, Wei-Qiang; Montironi, Carla; Bassaganyas, Laia; Moeini, Agrin;

(...)

Thung, Swan N.; Roayaie, Sasan; Villanueva, Augusto; Schwartz, Myron E.; Llovet, Josep M.;.

Referencia: HEPATOLOGY 2018.
Integrative molecular classification of extrahepatic cholangiocarcinoma

Autores:
Montal, R.; Leow, W. Q.; Montironi, C.; Bassaganyas, L.; Moeini, A.;

(...)

Thung, S.; Roayaie, S.; Villanueva, A.; Schwartz, M.; Llovet, J. M.;.

Referencia: JOURNAL OF HEPATOLOGY, SUPPLEMENT 2018.
Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”

Autores:
Montal R.; Lencioni R.; Llovet J.;

Referencia: JOURNAL OF HEPATOLOGY 2017.
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Autores:
Lencioni R; Montal R; Torres F; Park JW; Decaens T;

(...)

Assenat E; Kang YK; Lim HY; Walters I; Llovet JM .

Referencia: JOURNAL OF HEPATOLOGY 2017.
Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.

Autores:
Moeini, Agrin; Sia, Daniela; Zhang, Zhongyang; Camprecios, Genis; Stueck, Ashley;

(...)

Hao, Ke; Villanueva, Augusto; Thung, Swan N; Schwartz, Myron E; Llovet, Josep M.

Referencia: Journal Of Hepatology 2017.
Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy

Autores:
Rovira, A; Tornero, J; Oliva, M; Taberna, M; Montal, R;

(...)

Mari, A; Vinals, JM; Lozano, A; Mesia, R; Manos, M.

Referencia: HEAD AND NECK 2017; 39(1):116-121.

Proyectos destacados

Oncogenic drivers and poor prognosis signatures

Investigador/a principal: Josep Maria Llovet Bayer

Financiador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede)

Código: SAF-2013-41027

Duración: 01/01/2014 - 01/01/2016
Integrative genomic analysis of human intrahepatic cholangiocarcinoma

Investigador/a principal: Josep Maria Llovet Bayer

Financiador: Asociación Española Contra el Cáncer

Código: AECC_GrupoEstable11

Duración: 01/09/2011 - 31/08/2018
Biomaker study for identification of responders to sorafenib, STORM trial

Financiador: BAYER PHARMACEUTICALS

Duración: 01/01/2009

Robert Montal

Publicaciones destacadas

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

Molecular therapies and precision medicine for hepatocellular carcinoma

Molecular Classification and Potential Therapeutic Targets in Extrahepatic Cholangiocarcinoma

Integrative molecular classification of extrahepatic cholangiocarcinoma

Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.

Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy

Proyectos destacados

Oncogenic drivers and poor prognosis signatures

Integrative genomic analysis of human intrahepatic cholangiocarcinoma

Biomaker study for identification of responders to sorafenib, STORM trial

Suscríbete a la Newsletter del Clínic